Estados Unidos · Bolsa y Finanzas · Morningstar

Nanoscope Therapeutics to Participate in Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting

Publicado por Morningstar · Estados Unidos hace 17 h

Four-year REMAIN data from the RESTORE Phase 2b/3 trial of MCO-010 in retinitis pigmentosa and a scientific poster on dry AMD to be presented at the AAO 2026 Annual Meeting,…

Leer el artículo completo en Morningstar Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.morningstar.com)

Nanoscope Therapeutics to Participate in Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting

También te puede interesar

UBS to shed fund administration business acquired through Credit Suisse merger

Trump allows cheaper, dyed diesel on highways to blunt historic fuel-cost spike ahead of midterms

True Food Kitchen filed for bankruptcy and closed 12 restaurants

Japan Courts Saudi Arabia and UAE as Asia's Oil Supply Fears Persist

The VIX of bonds is rising but bitcoin and stocks aren't hearing it yet

Best Oil Stocks Right Now

Nanoscope Therapeutics to Participate in Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting

Compartir

También te puede interesar

UBS to shed fund administration business acquired through Credit Suisse merger

Trump allows cheaper, dyed diesel on highways to blunt historic fuel-cost spike ahead of midterms

True Food Kitchen filed for bankruptcy and closed 12 restaurants

Japan Courts Saudi Arabia and UAE as Asia's Oil Supply Fears Persist

The VIX of bonds is rising but bitcoin and stocks aren't hearing it yet

Best Oil Stocks Right Now